LT3049417T - Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof - Google Patents

Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof

Info

Publication number
LT3049417T
LT3049417T LTEP14750672.9T LT14750672T LT3049417T LT 3049417 T LT3049417 T LT 3049417T LT 14750672 T LT14750672 T LT 14750672T LT 3049417 T LT3049417 T LT 3049417T
Authority
LT
Lithuania
Prior art keywords
pyrazines
pyridines
pyrimidines
uses
btk inhibitors
Prior art date
Application number
LTEP14750672.9T
Other languages
Lithuanian (lt)
Inventor
Lesley Liu-Bujalski
Ngan NGUYEN
Hui QIU
Reinaldo Jones
Igor Mochalkin
Richard D. Caldwell
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201361860401P priority Critical
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Priority to PCT/US2014/048810 priority patent/WO2015017502A1/en
Publication of LT3049417T publication Critical patent/LT3049417T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/398Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a bacteria
    • Y02A50/399Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a bacteria of the genus Borrellia
    • Y02A50/401Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a bacteria of the genus Borrellia the bacteria being Borrelia burgdorferi, i.e. Lyme disease or Lyme borreliosis
LTEP14750672.9T 2013-07-31 2014-07-30 Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof LT3049417T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201361860401P true 2013-07-31 2013-07-31
PCT/US2014/048810 WO2015017502A1 (en) 2013-07-31 2014-07-30 Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
LT3049417T true LT3049417T (en) 2019-02-11

Family

ID=51303133

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14750672.9T LT3049417T (en) 2013-07-31 2014-07-30 Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof

Country Status (22)

Country Link
US (2) US9738648B2 (en)
EP (1) EP3049417B1 (en)
JP (1) JP6612751B2 (en)
KR (1) KR20160036053A (en)
CN (1) CN105814057B (en)
AU (1) AU2014296261B2 (en)
CA (1) CA2918242A1 (en)
DK (1) DK3049417T3 (en)
ES (1) ES2706150T3 (en)
HR (1) HRP20190054T1 (en)
HU (1) HUE042111T2 (en)
IL (1) IL243844A (en)
LT (1) LT3049417T (en)
MX (1) MX367085B (en)
PL (1) PL3049417T3 (en)
PT (1) PT3049417T (en)
RS (1) RS58361B1 (en)
RU (1) RU2016106760A (en)
SG (2) SG11201600159TA (en)
SI (1) SI3049417T1 (en)
WO (1) WO2015017502A1 (en)
ZA (1) ZA201600564B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35464A (en) 2013-03-15 2014-10-31 Araxes Pharma Llc KRAS G12C covalent inhibitors.
TWI659021B (en) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Inhibitors of kras g12c
EP3280708A1 (en) 2015-04-10 2018-02-14 Araxes Pharma LLC Substituted quinazoline compounds and methods of use thereof
MX2017013275A (en) 2015-04-15 2018-01-26 Araxes Pharma Llc Fused-tricyclic inhibitors of kras and methods of use thereof.
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
JP2018533611A (en) 2015-11-16 2018-11-15 アラクセス ファーマ エルエルシー 2-Substituted quinazoline compounds containing substituted heterocyclic groups and methods of using the same
CN107021963A (en) 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 Pyrazole fused ring analog derivative, its preparation method and its application in treating cancer, inflammation and immunity disease
JP2019528275A (en) * 2016-08-16 2019-10-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Oxo-imidazopyridines and their use as reversible BTK inhibitors
EP3519402A1 (en) 2016-09-29 2019-08-07 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3523289A1 (en) 2016-10-07 2019-08-14 Araxes Pharma LLC Heterocyclic compounds as inhibitors of ras and methods of use thereof
CN106831787B (en) * 2017-01-20 2018-10-23 成都倍特药业有限公司 Compound and its preparation method and application as bruton's tyrosine kinase inhibitor
US20190382377A1 (en) * 2017-01-26 2019-12-19 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
SU1212012A1 (en) * 1984-10-05 1996-03-20 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Derivatives of 4,5-dihydropirrolo[1,2,3-e,<d>] pteridine possessing antitumoral activity and method of obtaining the same
RU2358975C2 (en) * 2003-08-26 2009-06-20 Тейдзин Фарма Лимитед Pyrrolopyrimidinone derivatives
US20050080053A1 (en) * 2003-08-29 2005-04-14 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
RU2389731C2 (en) 2004-06-02 2010-05-20 Такеда Фармасьютикал Компани Лимитед Condensed heterocyclic compound
AU2005266803B2 (en) * 2004-07-30 2011-10-27 Methylgene Inc. Inhibitors of VEGF receptor and HGF receptor signaling
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
TW200730527A (en) * 2005-12-02 2007-08-16 Takeda Pharmaceuticals Co Fused heterocyclic compound
KR20090097908A (en) * 2006-12-06 2009-09-16 베링거 인겔하임 인터내셔날 게엠베하 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
CN101611041A (en) * 2006-12-12 2009-12-23 武田药品工业株式会社 Fused heterocyclic compound
GB0708141D0 (en) * 2007-04-26 2007-06-06 Syngenta Participations Ag Improvements in or relating to organic compounds
US20090233937A1 (en) * 2008-03-12 2009-09-17 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2010036910A1 (en) * 2008-09-26 2010-04-01 Yoshikazu Ohta Heart protection by administering an amp-activated protein kinase activator
CA2774579C (en) * 2009-10-08 2015-12-15 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
KR101483215B1 (en) * 2010-01-29 2015-01-16 한미약품 주식회사 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinases
WO2012150866A1 (en) * 2011-05-03 2012-11-08 Industrial Research Limited Phosphoribosyltransferase inhibitors and uses thereof
US9187487B2 (en) * 2011-05-17 2015-11-17 Principia Biopharma, Inc. Azaindole derivatives as tyrosine kinase inhibitors
US9376438B2 (en) * 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
PE20141681A1 (en) 2011-07-19 2014-11-14 Merck Sharp And Dohme B V BTK inhibitors
CA2849340A1 (en) * 2011-09-20 2013-03-28 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors

Also Published As

Publication number Publication date
CN105814057A (en) 2016-07-27
CN105814057B (en) 2019-05-03
AU2014296261A1 (en) 2016-02-11
MX2016001146A (en) 2016-04-29
MX367085B (en) 2019-08-05
US10005784B2 (en) 2018-06-26
KR20160036053A (en) 2016-04-01
PL3049417T3 (en) 2019-03-29
SG10201900025UA (en) 2019-02-27
SI3049417T1 (en) 2019-03-29
RU2016106760A (en) 2017-09-04
US9738648B2 (en) 2017-08-22
CA2918242A1 (en) 2015-02-05
IL243844D0 (en) 2016-04-21
EP3049417A1 (en) 2016-08-03
IL243844A (en) 2019-10-31
ES2706150T3 (en) 2019-03-27
PT3049417T (en) 2019-01-24
JP6612751B2 (en) 2019-11-27
WO2015017502A1 (en) 2015-02-05
JP2016531119A (en) 2016-10-06
DK3049417T3 (en) 2019-01-14
US20170226113A1 (en) 2017-08-10
US20160159804A1 (en) 2016-06-09
AU2014296261B2 (en) 2018-11-15
RS58361B1 (en) 2019-03-29
HUE042111T2 (en) 2019-06-28
SG11201600159TA (en) 2016-02-26
HRP20190054T1 (en) 2019-02-22
EP3049417B1 (en) 2018-10-17
ZA201600564B (en) 2019-04-24

Similar Documents

Publication Publication Date Title
JO3314B1 (en) Novel Amino Pyrimidine Derivatives
HK1207069A1 (en) Heterocyclic compounds and uses thereof
HK1219326A1 (en) Advanced authentication techniques and applications
LT2997023T (en) Bipyrazole derivatives as jak inhibitors
HK1208681A1 (en) Pyridinone and pyridazinone derivatives
IL240836D0 (en) Heterocyclic compounds and uses thereof
RU2016118981A (en) Pyrimidine fgfr4 inhibitors
AP201407844A0 (en) Substituted annulated pyrimidines and triazines, and use thereof
EP2968337A4 (en) Heteroaryl compounds and uses thereof
SI3076813T1 (en) Non-tobacco nicotine-containing article
SG10201708090TA (en) Microcrystalline diketopiperazine compositions and methods
SG11201600062RA (en) Pyrimidine derivatives as kinase inhibitors
EP2948458A4 (en) Btk inhibitors
SG11201600707QA (en) Substituted aminopyrimidine compounds and methods of use
LT3060550T (en) Heteroaryl compounds as btk inhibitors and uses thereof
EP3097078A4 (en) Pyridines and pyrimidines and use thereof
HK1212345A1 (en) 4-substituted pyrrolo- and pyrazolo-diazepines 4-
GB201300304D0 (en) Benzylamine derivatives
EP3083606A4 (en) Pyrimidines and use thereof
AU2014329392A1 (en) Heterocyclic compounds and uses thereof
IL240195A (en) Pyridone amide compounds, compositions comprising same and uses thereof
SG11201505974VA (en) Trifluormethyl-substituted ring-fused pyrimidines and use thereof
SG11201602445SA (en) Heterocyclic compounds and uses thereof
AU353315S (en) Lounge setting
HK1225383A1 (en) Diazepane derivatives and uses thereof